HIMS INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Hims & Hers Health, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers Health, Inc. (NYSE: HIMS) focused on whether Hims & Hers and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in the Hims & Hers investigation or if you are a Hims & Hers investor who suffered a loss and would like to learn more, you can provide your information here:
THE COMPANY: Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products.
THE REVELATION: On June 23, 2025, Novo Nordisk A/S announced that it 'terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.' On this news, the price of Hims & Hers stock fell more than 34%.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
BlackBerry Ltd (BB) Q1 2026 Earnings Call Highlights: Surpassing Expectations and Raising Guidance
Total Revenue: $121.7 million, exceeding guidance. Adjusted EBITDA: $16.4 million, a 55% year-over-year increase. Non-GAAP EPS: Positive $0.02, beating guidance. Operating Cash Usage: $18 million, better than expected. Share Buyback: $10 million worth of shares repurchased. QNX Revenue: $57.5 million, 8% year-over-year growth. Secure Communications Revenue: $59.5 million, meeting the top end of guidance. Annual Recurring Revenue (ARR): $209 million for Secure Communications. Licensing Revenue: $4.7 million for the quarter. Total Cash and Investments: $382 million, a decrease of $28 million during the quarter. Full Year Revenue Guidance: Raised to $508 million to $538 million. Full Year Adjusted EBITDA Guidance: Raised to $72 million to $87 million. Warning! GuruFocus has detected 3 Warning Signs with BB. Release Date: June 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BlackBerry Ltd (NYSE:BB) exceeded revenue expectations for the quarter, reporting $121.7 million, surpassing the top end of guidance. The company achieved a significant year-over-year growth in adjusted EBITDA, increasing by over 55% to $16.4 million. Non-GAAP earnings per share were positive at $0.02, beating guidance. BlackBerry Ltd (NYSE:BB) announced a $100 million share buyback program, demonstrating confidence in its financial strategy and shareholder value. The QNX division showed strong performance with revenue of $57.5 million, representing 8% year-over-year growth despite challenges in the automotive market. The company faces macroeconomic uncertainties, particularly in the automotive sector, which could impact future royalty revenues. There were some delays in customer buying decisions due to market uncertainties, affecting the QNX division. The licensing division's revenue was slightly below expectations due to lower revenue from existing licensing arrangements. Operating expenses faced headwinds from foreign exchange fluctuations, particularly due to a weakening US dollar. Cash used by operations was $18 million, reflecting seasonal low cash flow and restructuring costs. Q: Can you provide more clarity on the potential impact of production schedule changes on QNX revenue? A: Tim Foote, Chief Financial Officer: The Q2 royalty revenue for QNX is based on Q1 production. We have priced in a reasonable amount of risk in our guidance to account for potential disruptions, even though we haven't fully seen them yet. Q: How confident are you in the market outlook for the rest of the year given the current uncertainties? A: Tim Foote, Chief Financial Officer: The situation is fluid, and while some customers have withdrawn guidance, we maintain ours, indicating a certain level of visibility. We are confident due to our diversified revenue streams, including professional services and development seats. Q: Can you elaborate on the growth and significance of the SDP 8.0 pipeline? A: John Giamatteo, President - Cyber Security: The SDP 8.0 pipeline has grown by 55% and is gaining interest not only in automotive but also in robotics and industrial automation. It's one of our hottest products, indicating strong demand across various sectors. Q: What is your approach to the share buyback program? A: Tim Foote, Chief Financial Officer: The buyback program is flexible and will consider factors like cash flow, share price, and alternative capital uses. It is not a linear process but will focus on maximizing shareholder value. Q: What trends are you seeing in US federal defense spending, and which BlackBerry products are gaining traction? A: John Giamatteo, President - Cyber Security: We see increased interest in secure communications due to geopolitical dynamics. Governments are focusing on data sovereignty and mission-critical communications, which align well with our product offerings. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Takeda Announces New Assignments of Directors
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company's values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success. Details of the new assignments are as follows: 1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective June 25, 2025) 2. Directors Who Are Audit and Supervisory Committee Members 3. New Assignment of Nomination Committee and Compensation Committee Members (Effective June 25, 2025) Nomination committee: Masami Iijima (Chairperson), Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel and Yoshiaki Fujimori (Observer: Christophe Weber) Compensation committee: Emiko Higashi (Chairperson), John Maraganore, Michel Orsinger, Miki Tsusaka and Kimberly A. Reed About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Business Insider
2 hours ago
- Business Insider
Canaccord Genuity Sticks to Their Buy Rating for Bank Of Montreal (BMO)
Canaccord Genuity analyst Matthew Lee maintained a Buy rating on Bank Of Montreal (BMO – Research Report) today and set a price target of C$166.00. The company's shares closed today at $106.73. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Lee covers the Industrials sector, focusing on stocks such as CAE, Air Canada, and Diversified Royalty Corp. According to TipRanks, Lee has an average return of 13.1% and a 65.05% success rate on recommended stocks. In addition to Canaccord Genuity, Bank Of Montreal also received a Buy from RBC Capital's Darko Mihelic in a report issued on June 9. However, on the same day, Barclays downgraded Bank Of Montreal (NYSE: BMO) to a Hold. BMO market cap is currently $76.08B and has a P/E ratio of 13.59.
